Oculus Innovative Sciences, Inc. (NASDAQ: OCLS) has designed a humanitarian program to respond to unexpected disasters—floods, earthquakes, tsunamis, hurricanes, epidemics and even man-made calamities—by providing product (such as food or medical assistance) to these victims. The product will be available … Continue reading →

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs.  Galmed … Continue reading →

RestorGenex Corp. (OTCQB: RESX) is a specialty biopharmaceutical company focused on the development of a portfolio of first-in-class therapeutic products to treat diseases across the oncologic, ophthalmologic and dermatologic space. The company’s lead product is a novel PI3K/Akt/mTOR pathway inhibitor … Continue reading →

Finjan Holdings, Inc. (NASDAQ: FNJN) offers investors a diversified and unique vehicle for investing in cybersecurity-related intellectual property-backed technologies under the guidance of a proven team. Finjan’s commitment to innovation in the security space continues through its investments which have … Continue reading →

Check-Cap Ltd. (NASDAQ: CHEK) is a clinical stage medical diagnostics company leading the development of the first ingestible imaging capsule that utilizes low-dose X-rays for CRC screening. The Check-Cap device requires no bowel preparation or invasive procedures, and is designed … Continue reading →

Nephros, Inc. (OTCBB: NEPH), a commercial stage medical device company, develops and sells high-performance liquid purification ultra-filters and an online mid-dilution hemodiafiltration system for use with a hemodialysis machine for the treatment of patients with end stage renal disease. Its … Continue reading →

TapImmune Inc. (OTCQB: TPIV) is an immunotherapy company specializing in the development of innovative technologies for the treatment of cancer and infectious diseases. The company’s peptide or nucleic acid-based immunotherapeutics comprise one or more naturally processed epitopes designed to comprehensively … Continue reading →

InspireMD, Inc. (NYSE: NSPR) was founded in 2005 with the purpose of creating a technology that could solve the problem of embolization in high risk vascular procedures. The company has grown to include a portfolio of embolic protection systems, which … Continue reading →

Cel-Sci Corp. (NYSE: CVM) aims to find the best way to activate the immune system to fight cancer and infectious diseases. The company’s lead investigational therapy, Multikine (Leukocyte Interleukin, Injection), is currently being studied in a pivotal phase 3 clinical … Continue reading →

Pulmatrix, Inc. (NASDAQ: PULM) is developing innovative inhaled therapies to address serious pulmonary disease using its clinically validated, proprietary iSPERSE technology. Leveraging the unique capabilities of iSPERSE to dramatically advance inhalation technology, the company means to create new therapies to … Continue reading →